The National Institutes of Health Notifies ZZ Biotech and USC Keck School of Medicine of Intent to Grant $20 Million to Conduct a Pivotal Phase 3 Clinical Trial of 3K3A-APC for Stroke

3K3A-APC Granted Fast-Track Designation by FDA with Multinational Clinical Trial to Run Through NIH StrokeNet Houston, TX, January 26, 2021 – In a significant development for the treatment of acute ischemic stroke, the National Institute of Neurological Disorders and Stroke (NINDS), part of the U.S. National Institutes of Health (NIH), informed ZZ Biotech and researchers…

Read More

ZZ Biotech Announces First Patients Dosed in Phase 2 Clinical Trial of 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS)

Houston, TX December 2, 2021 — ZZ Biotech, a clinical stage biopharmaceutical company developing the experimental drug 3K3A-APC for some of the biggest unmet needs in stroke, neurodegenerative disease and chronic wound healing, today announced that the first patients have been dosed in a Phase 2 clinical trial evaluating 3K3A-APC for the treatment of amyotrophic…

Read More